Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lemborexant PD Study in Korean Insomnia Patients
NCT05594589Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Nov 2022
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of lemborexant in insomnia disorder (3 arms), sponsored by Eisai Co., Ltd. Primary endpoint: Latency to Persistent Sleep at Day 30. Started Nov 2022; status: completed.
02
Drugs
lemborexant
03
Conditions
insomnia disorder
Beyond the preview
Go deeper on NCT05594589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05594589.